Eupraxia Pharmaceuticals Files 6-K
Ticker: EPRX · Form: 6-K · Filed: May 7, 2025 · CIK: 1581178
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, annual-report
TL;DR
Eupraxia Pharma (EPRX) filed a 6-K on 5/7/25, confirming Canadian HQ and 40-F annual report filing.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 7, 2025, reporting as a foreign private issuer. The company is incorporated in Canada and its principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia. The filing indicates that Eupraxia Pharmaceuticals Inc. will file its annual reports under cover of Form 40-F.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals Inc.'s reporting status and location, which is important for investors tracking the company's regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain significant new financial or operational information.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- 001-41923 (company) — SEC File Number
- 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4 (company) — Principal Executive Office Address
- May 7, 2025 (date) — Filing Date
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed by Eupraxia Pharmaceuticals Inc. for the month of May 2025.
Where is Eupraxia Pharmaceuticals Inc. headquartered?
Eupraxia Pharmaceuticals Inc.'s principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada.
Which form will Eupraxia Pharmaceuticals Inc. use for its annual reports?
Eupraxia Pharmaceuticals Inc. will file its annual reports under cover of Form 40-F.
What is the SEC file number for Eupraxia Pharmaceuticals Inc.?
The SEC file number for Eupraxia Pharmaceuticals Inc. is 001-41923.
When was this Form 6-K filed?
This Form 6-K was filed on May 7, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 7, 2025 regarding EUPRAXIA PHARMACEUTICALS INC. (EPRX).